• Satona Tanaka, Mamoru Takahashi, Hidenao Kayawake, Yojiro Yutaka, Akihiro Ohsumi, Daisuke Nakajima, Kohei Ikezoe, Kiminobu Tanizawa, Tomohiro Handa, and Hiroshi Date.
• Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan. Electronic address: satonat@kuhp.kyoto-u.ac.jp.
• J. Thorac. Cardiovasc. Surg. 2024 Oct 10.

ObjectiveTo explore the characteristics and prognostic impact of chronic lung allograft dysfunction (CLAD) after deceased-donor lung transplantation and living-donor lobar lung transplantation, wherein the lower lobes from 2 donors are usually transplanted into one recipient.MethodsThe clinical data of 123 deceased-donor and 67 living-donor lung transplantations performed in adult patients at our institution between June 2008 and September 2019 were retrospectively reviewed. The cumulative incidence of CLAD was evaluated on a per-recipient and per-donor graft basis using the Kaplan-Meier method.ResultsA smaller number of human leukocyte antigen mismatches, shorter ischemic time, and lower incidence of grade 3 primary graft dysfunction were observed in living-donor transplantation than in deceased-donor transplantation (P < .001). Restrictive allograft syndrome-type CLAD occurred in 9 (20.9%) of 43 patients with CLAD after deceased-donor transplantation and 9 (45.0%) of 20 patients with CLAD after living-donor transplantation. CLAD occurred unilaterally in 15 patients (75.0%) after bilateral living-donor transplantation. Despite the greater incidence of restrictive allograft syndrome-type CLAD after living-donor transplantation, the overall survival rates after the transplantation and survival rates after the onset of CLAD were comparable between the patients receiving deceased-donor transplants and living-donor transplants. The cumulative incidence of CLAD per recipient was similar between recipients of deceased-donor and the living-donor transplants (P = .32). In the per-donor graft analysis, the cumulative incidence of CLAD was significantly lower in the living-donor grafts than in the deceased-donor grafts (P = .003).ConclusionsThe manifestation of CLAD after living-donor lobar lung transplantation is unique and differs from that after deceased-donor lung transplantation.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

7 keywords...

hide…